CTOs on the Move

Texas Medical Association

www.texmed.org

 
Texas Medical Association was organized by 35 physicians in 1853 to serve the people of Texas in matters of medical care, prevention and cure of disease, and the improvement of public health. Today, with more than 56,000 physician and medical student members, TMA is the nation`s largest state medical society. TMA`s key objective is to improve the health of all Texans.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.texmed.org
  • 401 West 15th Street
    Austin, TX USA 78701
  • Phone: 512.370.1300

Executives

Name Title Contact Details

Similar Companies

Educational Resource Systems

Educational Resource Systems is a Red Bank, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SynGen

SynGen advances regenerative medicine and other emerging applications for high-value cells by providing researchers, clinicians and manufacturers with innovative, robust systems that improve the recovery, purity and viability of stem and other clinically important cells from umbilical cord blood, peripheral blood, bone marrow, and cell culture.

World Medical Solutions

World Medical Solutions is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Plugin Systems

Plugin Systems is a Nederland, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.